| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IGLC2 |
| Uniprot No | P0DOY2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-235aa |
| 氨基酸序列 | MASFPLLLTLLTHCAGSWAQSVLTQPPSASGTPGQRVPISCSGSSSNIGSNTVNWYQQFPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDDAVYHCATWDDNLNSWVFGGGTKLTVLSQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS |
| 分子量 | 51.2 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于重组人IGLC2蛋白的模拟参考文献(基于现有知识推测，请以实际文献为准)：
---
1. **文献名称**：Structural characterization of recombinant human IGLC2 and its role in antibody assembly
**作者**：Chen L, et al.
**摘要**：本研究通过大肠杆菌系统成功表达并纯化重组人IGLC2蛋白，利用X射线晶体学解析其三维结构，揭示其与免疫球蛋白重链的结合模式，为抗体工程设计提供结构基础。
2. **文献名称**：IGLC2 as a potential biomarker in autoimmune diseases: Recombinant protein-based analysis
**作者**：Martinez R, et al.
**摘要**：通过重组IGLC2蛋白检测发现，其在系统性红斑狼疮(SLE)患者血清中异常表达，表明该蛋白可能作为自身免疫疾病的诊断标志物，并探讨其与炎症通路的关联性。
3. **文献名称**：High-yield production of recombinant human IGLC2 in mammalian cell systems
**作者**：Wang Y, et al.
**摘要**：优化哺乳动物细胞表达系统(CHO细胞)实现IGLC2蛋白高效分泌，通过糖基化修饰分析证明其接近天然构象，为大规模抗体药物生产提供技术参考。
---
*注：以上文献为模拟生成，具体研究需检索PubMed/NCBI等数据库获取真实数据。建议以“IGLC2”、“recombinant immunoglobulin lambda chain”为关键词检索近年文献。*
The immunoglobulin lambda constant 2 (IGLC2) protein is a critical component of antibody molecules in humans. As part of the immunoglobulin light chain, IGLC2 forms the constant region of lambda-type antibody light chains, pairing with variable regions to create functional antigen-binding domains. This protein is encoded by the *IGLC2* gene located on chromosome 22q11.2. Antibodies with lambda light chains constitute approximately 40% of human antibodies, contributing to immune diversity alongside kappa light chains.
Recombinant human IGLC2 (rhIGLC2) is produced via genetic engineering, often in systems like *E. coli* or mammalian cells, enabling precise study of its structure and function. Its recombinant form allows researchers to investigate antibody assembly, stability, and interactions with heavy chains or antigens without relying on native biological samples.
Studies involving rhIGLC2 have implications for understanding immune disorders, such as light chain amyloidosis or lymphoproliferative diseases, where abnormal light chain production occurs. Additionally, it serves as a tool in therapeutic antibody development, diagnostics, and epitope mapping. Recent research also explores IGLC2's role in autoimmune diseases and its potential as a biomarker. The availability of rhIGLC2 accelerates mechanistic studies and supports biopharmaceutical innovations requiring controlled, reproducible protein components.
×
